论文部分内容阅读
采用酶免疫荧光技术(FEIA)测定了20名正常健康者、25例发作期哮喘患者的血清嗜酸性细胞阳离子蛋白(ECP)浓度,并同时进行外周血嗜酸性细胞计数;在此基础上临床追踪观察了其中16例患者治疗前后ECP和EOS的波动情况。结果显示:①患者组血清ECP、EOS数较正常对照组明显增高(P<0.01);经治疗,二指标下降,较治疗前差异显著(分别P<0.01、P<0.05);②发作期血清ECP浓度和EOS数正相关(r=0.48,P<0.05),治疗后二者下降的幅度显著相关(r=0.65,P<0.01)。结论:嗜酸性细胞及其毒性蛋白颗粒—ECP是造成气道上皮损伤,促进哮喘炎症形成的重要介质。血清ECP检测目前已成为临床监测哮喘气道炎症活动情况、判断抗炎药物疗效以及预后的极佳指标。
Serum eosinophil cationic protein (ECP) levels were measured in 20 healthy subjects and 25 patients with asthma at the same time using enzyme-linked immunosorbent assay (FEIA). Peripheral blood eosinophils were also counted. On this basis, clinical follow-up The fluctuation of ECP and EOS in 16 patients before and after treatment was observed. The results showed that: (1) Serum ECP and EOS numbers in patients were significantly higher than those in normal control group (P <0.01); After treatment, the two indexes decreased significantly (P <0.01 and P <0.05, respectively) There was a positive correlation between ECP concentration and EOS number (r = 0.48, P <0.05). There was a significant correlation between ECP and EOS (r = 0.65, P <0.01). CONCLUSION: Eosinophils and their toxic protein granules-ECP are important mediators of airway epithelium injury and asthma inflammation. Serum ECP testing has now become an excellent indicator of clinically monitoring airway inflammation in asthma and judging the efficacy and prognosis of anti-inflammatory drugs.